Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Azurity Pharmaceuticals, Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners. Both actions are concentrated within 1 distinct art unit.
Examiner SOROUSH, LAYLA is the busiest with 1 pending office action. Although 2 different examiners are involved, the single art unit suggests a consistent technical focus for these pending matters. This arrangement allows practitioners to focus their research on the specific practices of 1 art unit while managing the individual preferences of 2 distinct examiners. With 2 pending office actions in total, the portfolio is small but benefits from the administrative simplicity of a single art unit. This concentration can be an advantage when developing a unified response strategy for the company's pharmaceutical filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18114469 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOF | HUANG, GIGI GEORGIANA | 10d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18114469 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOF | HUANG, GIGI GEORGIANA | 10d overdue |
| 18925887 | STABLE PHARMACEUTICAL COMPOSITIONS OF CYCLOPHOSPHAMIDE | SOROUSH, LAYLA | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18925887 | STABLE PHARMACEUTICAL COMPOSITIONS OF CYCLOPHOSPHAMIDE | SOROUSH, LAYLA | — | DP | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18114469 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOF | HUANG, GIGI GEORGIANA | 1613 | §103§112 | Final Rejection | 10d overdue | Pending | Feb 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial